Translate page

Collage 2023 iCMLf Prize winnersProfessor Irina Dyagil (Kyiv, Ukraine)
Head of the Department of Radiation Oncohematology
National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine
Kyiv (Ukraine)

Dr Kostyantyn Kotlyarchuk (Lviv, Ukraine)
Head of the Hematology Department
SI ‘Institute of Blood Pathology and Transfusion Medicine NAMS’,
Lviv (Ukraine)

Management of chronic myeloid leukemia (CML) improved dramatically over the last two decades. Introduction of imatinib and later other tyrosine kinase inhibitors (TKIs) changed prognostic expectations for these patients from quite poor to those approaching general population. However, availability of both therapeutic and diagnostic tools to achieve these results were and still are not the same in different countries around the world. Ukraine is one of the biggest countries in Europe with a total population of an estimated 40 million at the beginning of 2022. Already back then in relatively peaceful times, access to appropriate diagnostics and treatment for CML was quite challenging for Ukrainian patients and physicians. Now after almost two years of open war, this is a story of many struggles and losses and yet of many wins and successes.

01 1In Ukraine, CML accounts for approximately 3500 patients according to the most recent analyses and the average age at diagnosis is 48 – younger than one would expect in the majority of other countries. Up to the year 2000, most of these patients would be treated either with interferon or hydroxyurea or in some occasional cases with busulfan. Bone marrow transplantation could be performed in even more rare situations. Diagnostic possibilities were limited to peripheral blood hematology test, bone marrow cytology and karyotyping. At the beginning of the TKI era, thanks to the enthusiasm of patients and physicians, first attempts to use imatinib were made already in 2003 - 2004 - sooner than in some countries with higher economical standards. This initiative evolved into even broader access to the medication within clinical trials and starting from 2008 – within a dedicated national program “Right to Live” with the ultimate goal to create ongoing access to life-saving therapy for CML patients and to implement International diagnostics and treatment of CML in Ukraine.

These efforts led to a gradual improvement of all aspects of medical service for this cohort of patients. Currently, in most of the cases CML diagnostic process in Ukraine - apart from the basic evaluations - includes also karyotyping and both quantitative and qualitative PCR-investigation. Patients can be treated with imatinib as well as the 2nd generation TKIs including nilotinib, dasatinib and bosutinib according to the indication. Thanks to these possibilities, 10-year overall survival for CML patients in Ukraine is estimated at 78%.

However, there are many issues yet to be solved. From the diagnostic perspective it is critical to improve access to PCR-monitoring of CML, which is currently limited to very few dedicated institutions. Conduction of conventional or next generation sequencing for resistant patients requiring detection of BCR-ABL1 mutations is still impossible in Ukraine. Regarding the spectrum of treatment options patients are lacking access to later generation TKIs capable of overcoming the resistant mutant clones including T315I mutation. Possibility to utilize allogeneic hematopoietic stem cell transplantation as potentially curative option for refractory patients is also limited to very few procedures per year. With the beginning of an open military intervention, in addition to the issues described above, the Ukrainian hematological community had to also face situations, in which even basic medical service could be unavailable for patients located in areas most affected by the war.

02 2Taking into account all the obstacles, challenges and unfavorable circumstances, one would hardly expect medical service for CML in Ukraine to improve significantly. Nevertheless, certain solutions are found and some successes have been achieved. Progress is seen regarding improved availability of PCR monitoring for CML, which is probably the most important tool to understand the course of the disease. In addition to one centre in Kyiv, a dedicated institution in Lviv and later some private institutions started monitoring CML patients with this method. Apart from local efforts, the development of PCR monitoring in Lviv was possible thanks to the support from the iCMLf within its “ICMLf Diagnosis and Testing Program”. International cooperation in these turbulent times is one of the most powerful solutions also for other issues like for example assessment of BCR-ABL1 mutations. Samples of these patients are investigated with support of MLL Münchner Leukämielabor in Germany. Patients requiring 3rd generation TKIs or treatments currently unavailable in Ukraine are either referred to hospitals in other countries or apply for medications within compassionate use program and other support programs including those by The Max Foundation.

Several years ago, transplantation activity in adult Ukrainian patients was limited only to autologous procedures. Despite obvious challenges, allogeneic transplantations for this cohort of patients were recently initiated.  The number of procedures performed in 2022 increased 7-fold as compared to 2021. These first steps are very promising and include not only the rising access to this critical treatment method but also the creation of the Ukrainian Association of Bone Marrow Transplantation and an active International cooperation within the Help for Ukrainian Hematology Patients (HUP) initiative in particular. Careful but visible restoration of clinical trial activity is also detected, which is a very important option not only in CML but in other malignant blood disorders as well.

04 4Progress in providing better service for CML patients means not only achievements in diagnostics and treatment – there are many other aspects that are important. Patient organizations are becoming more and more active and influential in Ukraine initiating educational and social events, participating in governmental boards responsible for medical decisions on the national level, integrating in international patient organizations and activities etc. There are ongoing research projects dealing with pregnancy in CML, TKI toxicity, disease course prognosis, treatment-free remission and many other issues.

One of the main priorities for the development of hematology in Ukrainian and the management of CML in particular, is International cooperation. Ukrainian researchers are participating in cooperative groups and networks including European LeukemiaNet, are taking part in joint projects and publications, which lift the standards of care for CML patients in the country to higher levels.

In conclusion, despite many challenges every effort is made by the hematological community in Ukraine (patients, physicians, researchers etc.) to bring medical service for CML in accordance with modern standards. International cooperation has been and continues to be crucial to keep CML treatment and diagnostics on an acceptable level during troubled times and to prepare for a fast development in more peaceful time once a normal life has been restored.

Contact:

Professor Irina Dyagil
Head of the Department of Radiation Oncohematology
National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv
leuk@ukr.net

Dr Kostyantyn Kotlyarchuk
Head of the Hematology Department
SI ‘Institute of Blood Pathology and Transfusion Medicine NAMS’, Lviv
hematology_k@yahoo.com

F. GuilhotProfessor François Guilhot (Poitiers, France)
Emeritus Professor of Hematology and the past Director of the Clinical Investigation Center
1402 INSERM in Poitiers (France)

When I began my research into the treatment of patients suffering from chronic myeloid leukaemia, there were few truly effective treatments available apart from haematopoietic stem cell transplantation, but the vital risk was high and, above all, few patients could be transplanted. As early as 1989, I had observed complete and lasting cytogenetic responses with the interferon + cytarabine combination, the only 2 drugs acting on leukemic stem cells at the time.

In 2003, following the initial phase 1 and 2 trials, we knew that imatinib had a particularly important anti-leukemic effect because it was targeted. But there was no proof of its efficacy as a first-line treatment, so a prospective phase 3 trial had to be set up in previously untreated patients.

CML French group ESH 2023 KopieThe "IRIS" trial was therefore carried out, comparing imatinib at a dose of 400 mg per day with the interferon + cytarabine combination. This comparison arm was chosen because I had demonstrated that the interferon + cytarabine combination significantly increased survival and had become the gold standard for the treatment of CML. After including 1106 patients, we showed that imatinib was more effective, with a significant increase in molecular response. To demonstrate the effect on survival, we were able - thanks to an excellent collaboration with Novartis - to carry out a comparison between the historical arm of our CML 91 trial involving the combination of interferon + cytarabine and the imatinib arm of the IRIS trial: this is the one and only proof of the positive effect of imatinib on patient survival.

OLYMPUS DIGITAL CAMERA         Following the IRIS trial, a number of unresolved questions remained. For example, was the 400 mg dose of imatinib sufficient and was there any point in testing combinations such as combining imatinib with interferon or cytarabine? With Brian Druker, Steve O'Brien and Joëlle Guilhot (my wife!), we wrote a clinical trial project, the 'SPIRIT' trial, which was to be conducted in the USA, the UK and France; but only France finally enrolled patients and published the results. This trial had four arms: Two arms with doses of 400 mg and 600 mg of imatinib, one arm with the imatinib-cytarabine combination, and one arm with the imatinib-pegylated interferon combination.

We demonstrated that the combination of imatinib and interferon significantly increased the molecular response, but survival at 15 years was the same for all four arms, at 80-85%, which is still very remarkable. We observed that if patients could continue interferon for at least one year, they had a high probability of being able to stop their treatment without risk.

In conclusion, it should be remembered that the immune system plays an important role in CML, and that interferon has had a remarkable effect in some patients who have been able to tolerate it long enough. However, its toxicity and its use by injection are difficult for patients to accept.

Contact:

Emeritus Professor of Hematology
Past Director of the Clinical Investigation Center
Centre d’Investigation Clinique
Inserm CIC 0802
CHU de Poitiers
f.guilhot@chu-poitiers.fr

02 22 jerry radichProfessor Jerry Radich (Seattle, USA)
Director of the Radich Laboratory and the Molecular Oncology Laboratory at the Fred Hutchinson Cancer Center in Seattle (USA)

I am honored beyond measure to receive the Rowley Prize in 2023. Dr. Janet Rowley was a remarkable physician, scientist, and (most of all), human. For me to be mentioned in the same sentence as Janet is both humbling and mindboggling, especially since I readily confess to drafting behind the wake of brilliance of others before me (many who have won this award in previous years).

I have been remarkably lucky. I got interested in CML because my first boss, Nobel Laureate, E. Donnall Thomas, had a special interest in it, and encouraged my participation in clinical transplantation and lab work focused on CML. I worked in the lab of Steve Collins, who was one of the first to study the molecular biology of CML progression, added by the then novel technique of PCR (done at first in water baths. An aside: we had the first automated PCR machine in the city of Seattle. I broke it in its inaugural run…). My good fortune continued when I was brought into the IRIS trial by my friend and colleague Brian Druker. From then on, I was off on an academic joy ride, meeting the most remarkable band of colleagues and friends that any worker, in any field, could ever ask for.

With our remarkable success in CML, many in the cancer field - especially funding agencies - wonder if CML is essential “done.” How much better can our therapies be? What new translatable knowledge can CML provide that will continue to guide the field (CML is, after all, the first and foremost example of the “precision medicine” movement)?

I would argue, a lot.

I think there are three essential questions we are still dealing with in CML, and all of them are important models to other cancers:

  1. Who responds to therapy?
  2. Who loses response (relapse/progression)?
  3. Who can have their treatment discontinued?

JRnotdeadWho responds to therapy? It is remarkable that in CML we can fairly predict outcomes based on a relatively short-term series of response landmarks. We have leveraged this into using BCR-ABL as a rapid surrogate for drug approval trials - a remarkable accomplishment that is the envy, and goal, of virtually all other malignancies. Indeed, in the U.S., there is large, funded effort in AML to perfect and standardize measurable residual disease to both guide therapy, and be used as an early endpoint for drug development - all based and guided by our work in CML. Moreover, work in CML has shown the huge importance of the immune system in influencing and maintaining disease response, and these findings are spurring work in other hematological and solid malignancies.

Who loses response? CML is the classic model of disease progression, as without intervention with TKI or transplant, all patients will eventually march from chronic phase to accelerated and blast phase. The biologic “clock” is still being investigated, but several lines of work have shown the similarities of outright progression and resistance. This work will likely inevitably map to other liquid diseases where progression occurs (MPN, MDS) as well as potentially solid tumors (prostate and colon cancer being good candidates).

Who can have their disease discontinued?  The amazing finding that a good proportion of CML patients can eventually discontinue therapy has spawned an industry of creative clinical trials and biological methodology to better predict and succeed treatment free remissions. The work has shown the biological importance in immune mechanisms in TFR, and the power of innovative technical measures such as duplex sequencing, digital PCR, and single cell ‘omics to predict outcomes. As treatments advance in other hematological malignancies, a few diseases are vying for the honor of “the next CML”, where considerations of treatment discontinuations pioneered in CML are promoted as the future models of therapy (looking at you, CLL).

Lastly, I had the honor of winning the iCMLf Prize in 2017 for work developing CML diagnostics for low- and middle-income countries. With the advent of new oral agents for other malignancies, those experimental strategies found to work for CML should be adaptable for new targets, allowing all patients in low resource areas to enjoy the same benefits of the cancer treatment revolution as those who live in richer countries.

Many, many thanks for all your past, present, and continued support. Anything I accomplished was done with you, and so I thankfully share this honor with you all.

Contact:

Jerald Radich, MD
Translational Science & Therapeutics Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Center
jradich@fredhutch.org

Clinical Publications Scientific Publications
December 2023
CML and the WHO: Why?
Berman E et al. J Clin Oncol, December 2023 (epub ahead of print)
Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications
Ouyaung D et al. Cancers(Basel), December 2023
– open access publication
Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML
Winn AN et al. JAMA Netw Open, December 2023
open access publication
 
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis
Wu A et al. Leukemia, December 2023
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group
Rivera D et al. Mod Pathol, December 2023
(epub ahead of print)
– open access publication
The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication
Accelerated-phase CML: de novo and transformed
Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023
– open access publication 
 

A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes
Zenebe B et al. Hematology Review, December 2023
– open access publication

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review
Atallah E et al. Ther Adv Hematol, December 2023
open access publication
C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells
Zehtabcheh S et al. Mol Biol Rep, December 2023

Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French
Réa D et al. Bull Cancer, December 2023
(epub ahead of print)
– open access publication 

The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia
Liu XY et al. Hematology, December 2023
– open access publication
 
Resistance mutations in CML and how we approach them - Review
Soverini S et al. Hematology Am Soc Educ Program, December 2023
– open access publication
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
Yin L et al. Hematology, December 2023
– open access publication
SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review
Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print) 
miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1
Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication
How to improve treatment-remission eligibility in CML? Review
Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication 
Osimertinib covalently binds to CD34 and eliminates progenitor cells
Xia L et al. Cancer Res, December 2023
(epub ahead of print)
The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
Liu L et al. Hematology, December 2023
– open access publication 
Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells
Yang Y et al. Hematology, December 2023
– open access publication
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019
Sasaki K et al. Cancer, December 2023
 
Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan
Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023
 
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans
Hofmann J et al. Leukemia, December 2023 – open access publication
 
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
Kongruang A et al. Hematology, December 2023
– open access publication
 
An update of the management of advanced phase chronic myeloid leukemia – Review
Short NJ et al. Curr Hematol Malig Rep, December 2023
 
Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic
Collins JB et al. J Oncol Pharm Pract, December 2023
(epub ahead of print)
– open access publication
 
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review
Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print)
 
Exploration of treatment-free remission in CML, based on molecular monitoring – Review
Zhang Z et al. Cancer Med, December 2023 (epub ahead of print)
– open access publication
 
November 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Cross NCP et al. Leukemia, November 2023
– open access publication
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation
Huuhtanen J et al. Leukemia, November 2023
(epub ahead of print)
– open access publication 
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study
Zambrotta GPM et al. Am J Hematol, November 2023
– open access publication
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Shin JE et al. Mol Cancer, November 2023
– open access publication
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia:
Results from the phase 4 BYOND study

Rosti G et al. Leukemia, November 2023
(epub ahead of print)
– open access publication
Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
Häselbarth L et al. BMC Cancer, November 2023
– open access publication 
Survival with chronic myeloid leukemia after failing milestones
Lauseker M et al. Leukemia, November 2023
– open access publication
 
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia?
Kantarjian HM Leukemia, November 2023
 
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib
Mulas O et al. Ann Hematol, November 2023
 
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
Park H et al. Ther Adv Hematol, November 2023
– open access publication

Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients
Rafiq Mohammed A et al. Gene, November 2023 


October 2023
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review
Aldapt MB et al. Oncology, October 2023
(epub ahead of print)
Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review
Verhagen NE et al. Pharmaceutics, October 2023
– open access publication
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia:
a systematic review and network analysis – Review
Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)
Mitochondrial complex I inhibition by homoharringtonine:
A novel strategy for suppression of chronic myeloid leukemia

Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions
Larfors G et al. Eur J Haematol, October 2023
– open access publication
A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells
Zhang X et al. Cell Mol Biol Lett, October 2023
– open access publication
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy
Khadadah FM et al. Leuk Res, October 2023
AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells
Lapa BS et al. Int J Mol, October 2023
– open access publication
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review
Kantarjian HM et al. Lancet Haematol, October 2023
Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis
Boucher L et al. Int J Mol, October 2023
– open access publication 
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results
Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
 
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report
Alshurufa A et al. Case Rep Oncol, October 2023
– open access publication
 
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia
Efficace F et al. Cancer, October 2023
(epub ahead of print)
 
September 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Kok CH et al. Blood Cancer J, Sept 2023
(epub ahead of print)
– open access publication 
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmunagathan N et al. Haematologica, Sept 2023
open access publication
Survival with chronic myeloid leukemia after failing milestones
Lauseker M et al. Leukemia, September 2023
(epub ahead of print) – open access publication 
New patterns of genetic instability in chronic myeloid leukemia: Interesting, but not ready for clinical use
Schiffer CA. Haematologica, Sept 2023
– open access publication
Treatment-free remission after dasatinib in patients with chronic myeloid leukemia in chronic-phase with deep molecular response: Final 5-year analysis of DASFREE
Shah NP et al. Br J Haematol, Sept 2023
- open access publication 
Aquired miR-142 deficit in leukemia stem cells suffices to drive chronic myeloid leukemia into blast crisis
Zhang B et al. Nat Commun, Sept 2023
– open access publication
The (near) miracle of therapy in chronic myeloid leukemia
Radich JP. Br J Haematol, Sept 2023
– open access publication
Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
Okabe S and Gotoh A. BMC Cancer, Sept 2023
Improvement, implementation, and evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach
Verweij L et al. J Med Internet Res, Sept 2023
- open access publication
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on TKI therapy predicts the imatinib treatment failure
Ratajczak B et al. Leuk Res, Sept 2023
– open access publication 
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
Kockerols C et al. Eur J Haematol, Sept 2023
(epub ahead of print)
MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review
Sing P. Med Oncol, Sept 2023
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukemia receiving initial imatinib therapy
Qi F et al. Leukemia, Sept 2023
 
Final report of TKI discontinuation trial with dasatinib for the second attempts of treatment-free remission after failing the first attempts with imatinb: Treatment-free Remission Accomplished by Dasatinib (TRAD) Study
Perusini MA et al. Br J Haematol, Sept 2023
(epub ahead of print)
 
Risk factors determining adherence to tyrosine kinase inhibitors in chronic myeloid leukemia
Del Rosario García B et al. J Oncol Pharm Pract, Sept 2023 (epub ahead of print)
 
The expanding CML treatment landscape: an introspective commentary
Lipton JH, Blood Cancer J, Sept 2023
(epub ahead of print) – open access publication
 

Bilateral massive retinal infiltrates: Sign of blast crisis in chronic myeloid leukemia
Patel A et al. Ophthalmology, Sept 2023
(epub ahead of print)


Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice
Ielo C et al. Leuk Lymphoma, Sept 2023
(epub ahead of print)

 
Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase
Oyogoa E et al. Front Oncol, Sept 2023
– open access publication
 
August 2023
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies
Bhattacharjee U et al. Leuk Res, August 2023 (epub ahead of print) 
Using natural killer cell-derived exosomes as a cell-free therapy for leukemia
Samara A et al. Hematol Oncol,
August 2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission
Laganà A et al. Eur J Haematol, August 2023 (epub ahead of print) 

NDRG3 regulates imatinib resistance by promoting ß-catenin accumulation in the nucleus in chronic myelogenous leukemia
Wang X et al. Oncol Rep, August 2023
– open access publication

Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: A National PopulationBased Cohort Study
Huang CE et al. Oncologist, August 2023
(epub ahead of print)
– open access publication 
Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia
Martínez-Castillo M et al. Leuk Res, August 2023
Measuring chronic myeloid leukemia TKI-related toxic effects in the real-world:
a systematic review and critical assessment of content validity of patient-reported outcomes measures - Review
Smit Y et al. Lancet Haematol, August 2023
(epub ahead of print) 
Mitochondrial dysfunction in cardiotoxicity induced by BCR-ABL1 tyrosine kinase inhibitors – underlying mechanisms, detection, potential therapies – Review
Sun S et al. Cardiovasc Toxicol,
August 2023
Real-world experience with ponatinib therapy in chronic-phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
Abdelmagid MG et al. Blood Cancer J, August 2023 (epub ahead of print)
– open access publication 

Crizotinib acts as a ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL T315I and BCR-ABL1 T315I-E255K
Mian AA et al. Ann Hematol, August 2023
– open access publication

Reverse transcription can critically impact the diagnostic outcome of BCR::ABL1 quantitative real-time RT-PCR
Spiess B et al. Cancers(Basel)
– open access publication
MEK1/2 regulates normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
Mazzera L et al. Leukemia, August 2023
– open access publication 
Interferon in chronic myeloid leukemia: Is it useful for treatment-free remission?
Breccia M and Saglio G. Br J Haematol, August 2023 (epub ahead of print)
– open access publication
High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
Aghel N et al. Leuk Lymphoma, August 2023
(epub ahead of print) 
Step-in dosing of bosutinib in patients with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Isfort S et al. Ann Hematol, August 2023
(epub ahead of print)
– open access publication
Food for thought (and CML survival)
Sezaki M and Huang G. Blood, August 2023 
Population modelling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
Garret M et al. Cancer Med, August 2023
(epub ahead of print)
– open access publication
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
Rattigan KM et al. Nat Commun, August 2023
– open access publication 
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy
Pagani IS et al. Blood, August 2023 (epub ahead of print)
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associations with each resistance mechanisms
Leow BCS et al. Sci Rep, Aug 2023
– open access publication 
July 2023
Immune modulation in chronic myeloid leukemia patients treated with nilotinib and interferon-alpha
Irani YD et al. Br J Haematol, July 2023
(epub ahead of print)
Genetic separation of chronic myeloid leukemia stem cells from normal hematopietic stem cells at single-cell resolution
Chen Y et al. Leukemia, July 2023
– open access publication
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
Cortes JE et al. Haematologica, July 2023
(epub ahead of print)
– open access publication
Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukemia stem cells
Rattigan KM et al. EMBO Rep, July 2023
(epub ahead of print)
– open access publication
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
Balsat M et al. Leuk Res, July 2023
Profiling of miRNAs and their interfering targets in peripheral blood mononuclear from patients with chronic myeloid leukemia
Wu SC et al. Front Oncol, July 2023
– open access publication
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia
Huguet F et al. Expert Rev Hematol, July 2023
(epub ahead of print)
Control of PH+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors
Ansari S and Verma M. Med Oncol, July 2023
Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
Chen Y et al. Cancer Med, July 2023
(epub ahead of print)
– open access publication
HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway
Yin L et al. Hum Cell, July 2023

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era
Haddad FG et al. Am J Hematol, July 2023
(epub ahead of print)

Phenotypic and functional characterization of subpopulation of imatinib resistant chronic myeloid leukemia cell line
Hekmatshoar Y et al. Adv Med Sci, July 2023 (epub ahead of print)
Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia
Braga AGO et al. Hematol Transfus Cell Ther, July 2023 (epub ahead of print)
– open access publication

Histone demethylase PHF8 facilitates the development of chronic myeloid leukemia by directly targeting BCR::ABL1
Feng H et al. Br J Haematol, July 2023
(epub ahead of print)
– open access publication

Real-world management of CML: outcomes and treatment patterns
Held N and Atallah EL. Curr Hematol Malig Rep, July 2023 (epub ahead of print)
 
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
Jacobi H et al. Front Pharmacol, July 2023
– open access publication
 
Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient
Nohoglu Kantarci E et al. Cancer, July 2023
(epub ahead of print) 
 
June 2023
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro
Eckart F et al. Hamostaseologie, June 2023
– open access publication
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
Radich JP et al. Haematologica, June 2023 – open access publication 
Single cells tell multiple tales in CML
Ross DM. Blood, June 2023
– open access publication
Project Confirm: Accelerated drug approvals for chronic myeloid leukemia
Sweet KL et al. Clin Cancer Res, June 2023 
Association of pre-treatment bone marrow morphology and achievement of BCR-ABL1 transcript milestone in CML
Murkoviç M et al. Pathol Res Pract, June 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML
Tribelli M et al. Cancer, June 2023
(epub ahead of print)
– open access publication 
BCR-ABL promotes hematopoietic stem and progenitor cell formation in embryonic stem cells
Artus J et al. Exp Hematol, June 2023
(epub ahead of print)
Management of chronic myeloid leukemia patients in later lines: The role of ponatinib and new compounds - Review
Scalzulli E et al. Clin Lymphoma Myeloma Leuk, June 2023 
Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia – Review
Am Soc Clin Oncol Educ Book, June 2023
– open access publication
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress
Kantarjian HM and Tefferi A. Am J Hematol, June 2023 (epub ahead of print) – open access publication 
Chronic myeloid leukemia during pregnancy with placental involvement:
Case Report and Literature Review
Çobankent Aytekin E et al. Fetal Pediatr Pathol, June 2023
Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey
Chen H et al. Leuk Lymphoma, June 2023
(epub ahead of print)
  Switching from imatinib to nilotinib plus pegylated interferon α2b in chronic phase chronic myeloid leukemia failing to achieve deep molecular response:
clinical and immunologica effects
Geelen IGP et al. Ann Hematol, June 2023
  Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulation surviving
Yin SS et al. Cell Cycle, June 2023
– open access publication
  Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukemia cells
Tsubaki M et al. Cell Prolif, June 2023
– open access publication
May 2023
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S and Cortes J. Haematologica, April 2023
(epub ahead of print)
– open access publication 
Modulating retinoid-x-receptor alpha RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
Rajmani BM et al. Front Pharmacol, May 2023
- open access publication
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
Pavlovsky C et al. J Hematol Oncol, April 2023
– open access publication 
Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
Langhammer M et al. Leukemia, May 2023
(epub ahead of print)
– open access publication
Cardiovascular risk in chronic myeloid leukemia: A multidisplinary consensus on screening and management
Milojkovic D et al. Eur J Haematol, April 2023 (epub ahead of print)
– open access publication
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Hiroshi H et al. Sci Rep, May 2023
– open access publication 
Gene expression pattern of ESPL1, PTTG1 and PTTG1IP can potentially predict response to TKI first-line treatment of patients newly diagnosed CML
Christiani E et al. Cancers(Basel),
May 2023 – open access publication 
Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells
Qiu S et al. Blood, May 2023
(epub ahead of print) 
A pragmatic approach to managing long-term adverse effects in chronic myeloid leukemia treatment - Review
Lucero JA and Lipton JH. Curr Hematol Malig Rep,
May 2023 (epub ahead of print)
Frequency and driver mutation diversity in concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm
Langabeer SE et al. Int J Hematol, April 2023 (epub ahead of print) 
The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist - Review
Clements J et al. Future Oncol, May 2023
(epub ahead of print)
– open access publication
Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A.
Xu Y et al. Cancer, May 2023
– open access publication 
SOHO state of the art updates and next questions / Update on treatment-free-remission in chronic myeloid leukemia (CML) - Review
Mikhaeel S and Atallah E. Clin Lymphoma Myeloma Leuk, May 2023
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
Gao C et al. Front Pharmacol, April 2023
– open access publication 
Imatinib compared to second-generation tyrosine kinase inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
Yang S et al. Am J Hematol, May 2023
(epub ahead of print)
– open access publication 
Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
Mitrovsky O et al. PLoSOne, May 2023
– open access publication 
Response-based dosing for ponatinib: Model-based analyses of the dose-ranging OPTIC study
Hanley MJ et al. Clin Pharmacol Ther, May 2023
(epub ahead of print) 
Modeling global genomic instability in chronic myeloid leukemia (CML) using patient-derived induced pluripotent stem cells (iPSCs)
Telliam G et al. Cancers(Basel), May 2023
– open access publication
 
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review
Ali Hailan YM et al. Oncology, May 2023
– open access publication 
 
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Kaddoura R et al. Front Med, May 2023
– open access publication 
 
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplant - Review
Uhm J. Blood Res, April 2023
- open access publication
 
Developing therapeutic approaches for CML: a review
Kumar V et al. Mol Cell Biochem, May 2023
 
The EMA assessment of Asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with at least two tyrosine kinase inhibitors
Tesileanu CMS et al. Oncologist, May 2023 (epub ahead of print)
– open access publication
 
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase focusing on age and dose effects
Tokuhira M et al. Int J Hematol, May 2023
(epub ahead of print)

 

 
Impact of obesity surgery on tyrosine kinase inhibitor responses and survival outcomes in patients with chronic myeloid leukemia: Further data are still warranted!
Eskazan AE et al. Cancer, May 2023
(epub ahead of print)
 
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response
Tossoni L et al. Ann Hematol, May 2023
 
April 2023
The outcome of post-transplant asciminib in patients with CML
Fernando F et al. Bone Marrow Transplant, April 2023 (epub ahead of print)
New patterns of genetic instability in chronic myelogenous leukemia: interesting, but not ready for clinical use
Schiffer CA. Haematologica, April 2023
(epub ahead of print)
– open access publion
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
Réa D et al. Leukemia, April 2023 (epub ahead of print)
– open access publication
The structure of the hematopoietic system can explain chronic myeloid leukemia progression
Pérez-Jiménez M et al. Sci Rep, April 2023
– open access publication
Management of chronic myeloid leukemia in 2023 – Common ground and common sense - Review
Senapati J et al. Blood Cancer J, April 2023
– open access publication
Characterization of bone marrow niche in chronic myeloid leukemia patients identifies CXCL14 as a new therapeutic option
Polinska M et al. Blood, April 2023
(epub ahead of print)
Efficacy and safety of nilotinib in chronic myeloid leukemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study
Dulucq S et al. Br J Haematol, April 2023
(epub ahead of print)
– open access publication
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
Fiordi B et al. Haematologica, April 2023
(epub ahead of print)
– open access publication
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event
Tarantini F et al. Leuk Res, April 2023
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia
Zhong FM et al. Cancer Cell Int, April 2023
open access publication
Managing women of childbearing age with chronic myeloid leukemia: Safety and treatment considerations
Expert Rev Hematol, April 2023
(epub ahead of print)
Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia
Zhong FM et al. Cancer Cell Int, April 2023
– open access publication 
An analysis of dasatinib treatment patterns in patients with chronic myeloid leukemia after experiencing pleural effusion during dasatinib therapy
McBride A et al. Acta Haematol, April 2023
(epub ahead of print)  
 
Efficacy and safety of nilotinib as frontline therapy in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
Luciano L et al. Ann Hematol, April 2023
(epub ahead of print)
– open access publication
 
Applications of machine learning in chronic myeloid leukemia - Review
Elhadary M et al. Diagnostics(Basel),
April 2023 – open access publication
 
Breaking the mold: asciminib as a standard of care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting
Yilmaz R et al. Future Oncol, April 2023 (epub ahead of print)

 

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia – Review
Han JJ et al. Blood Res, April 2023
(epub ahead of print)
– open access publication
 
Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings - Review
Cheng F et al. Front Oncol, April 2023
– open access publication
 
Assessment of imatinib as a primary treatment of chronic myeloid leukemia in chronic phase: a Cohort Study
Merin D et al. J Oncol Pharm Pract,
April 2023
 
March 2023
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et al. Leukemia, March 2023
– open access publication
AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells
Lee YC et al. Biochem Pharmacol,
March 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Mauro MJ et al. Leukemia, March 2023
(epub ahead of print) – open access publication
The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere lengths in chronic myeloid leukemia
Deregowska A et al. J Cancer Res Clin Oncol, March 2023 (epub ahead of print) – open access publication
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Shanmunagathan N et al. Haematologica, March 2023 (epub ahead of print) – open access publication 
Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame imatinib-resistance in CML CD34+ cells
Xu X et al. Cell Commun Signal,
March 2023 – open access publication
Editorial: Advances in the treatment of chronic myeloid leukemia
Eskazan AE et al. Front Oncol, March 2023
– open access publication
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TFG-ß growth-suppressive signaling in BCR-ABL1-positive leukemia
Wang L et al. Signal Transduct Target Ther, March 2023 – open access publication
High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
Kockerols CCB et al. Haematologica, March 2023 (epub ahead of print) – open access publication 
The prognostic and therapeutic potential of HO-1 in leukemia and MDS – Review
Sadeghi M et al. Cell Commun Signal, March 2023 – open access publication
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis RM et al. Blood Adv, March 2023
(epub ahead of print) – open access publication
NOX2 and NOX4 control mitochondrial function in chronic myeloid leukemia
Romo-González M et al. Free Radic Biol Med, March 2023
– open access publication 
The economic burden of chronic myeloid leukemia in patients with later lines: Findings from a real-world analysis in Italy
Breccia M et al. Adv Ther, March 2023
– open access publication
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
Qiu Q et al. Signal Transduct Target Ther, March 2023 – open access publication 
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia
Krishnan V et al. Blood, March 2023 (epub ahead of print)
Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Kaehler M and Cascorti I. Handb Exp Pharmacol,
March 2023 (epub ahead of print) 
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, March 2023
(epub ahead of print)
 
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
Walia A and Prasad V. Blood Cancer J, March 2023 – open access publication
 
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia
Aleem A et al. Int J Hematol, March 2023
(epub ahead of print)
 
Association between bariatric surgery and outcomes in chronic myeloid leukemia
Haddad FG et al. Cancer, March 2023
(epub ahead of print) 
 
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase – Review
Choi EJ. Blood Res, March 2023
(epub ahead of print)
– open access publication 
 
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO study): study protocol for prospective, multicentre, single-arm trial
Djodikromo MF et a. BMC Cancer,
March 2023 – open access publication 

 

February 2023
 

Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells
Tsubaki M et al. BMB Rep, February 2023
– open access publication

Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for the novo lymphoid blast phase-chronic myeloid leukemia
Yang Z et al. Leuk Res, February 2023
(epub ahead of print)
Repurposing the Bis-Biguanide Alexidine in combination with tyrosine kinase inhibitors to eliminate leukemic stem/progenitor cells in chronic myeloid leukemia
Muselli F et al. Cancers(Basel), February 2023 – open access publication
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: characteristics, potential mechanism, and clinical management strategies – Review
Cheng F et al. Front Oncol, February 2023
– open access publication

Discovery of CZS-241: A potent, selective, and orally available Polo-like kinase 4 inhibitor for the treatment of CML
Sun Y et al. J Med Chem, February 2023

 
Cardiovascular toxicities associated with tyrosine kinase inhibitors - Review
Sahegh N et al. Curr Cardiol Rep, February 2023 (epub ahead of print)
Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia
Jiang B et al. Front Oncol, February 2023
– open access publication
The bone marrow immune environment in CML: Treatment responses, treatment-free remission and therapeutic vulnerabilities
Patterson SD & Copland M. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
– open access publication
A survey of patient experience in CML: American and Canadian Perspectives
Hillis C et al. Patient Prefer Adherence, February 2023
– open access publication
 
Importance of tyrosine kinase inhibitor treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-Free study
Yoshida C et al. Int J Hematol, February 2023
(epub ahead of print) – open access publication
 
Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network
Nunes RAB et al. Front Cardiovasc Med, February 2023 – open access publication 
 
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison
Hyland KA et al. Leuk Lymphoma, February 2023
 
Family planning and pregnancy in patients with chronic myeloid leukemia – Review
Berman E et al. Curr Hematol Malig Rep, February 2023 (epub ahead of print)
 
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modelling and pathway analysis
Radich JP et al. Haematologica, February 2023
(epub ahead of print) – open access publication
 
January 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in CML
Irani YD et al. Blood Adv, January 2023
(epub ahead of print)
– open access publication 
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Hochhaus A et a. Leukemia, January 2023
(epub ahead of print)
– open access publication
RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
Zhang H et al. Haematologica, January 2023
– open access publication
Matching adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E et al. J Caner Res Clin Oncol, January 2023 (epub ahead of print) – open access publication
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
Häselbarth L et al. Cancer Immunol Immunother, January 2023 (epub ahead of print)
– open access publication 
Allogeneic transplantation for chronic myeloid leukemia: I’m not dead yet!
Radich J. Am J Hematol, January 2023
– open access publication
mTORC2 is activated under hypoxia and could support chronic myeloid leukemia stem cells
Panuzzo C et al. Int J Mol Sci, January 2023
– open access publication 
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor
Bidikian A et al. Am J Hematol (epub ahead of print)
BH3 mimetics and TKI combined therapy for CML
Brumatti G et al. Biochem, January 2023
– open access publication 
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Jabbour EJ et al. Am J Hematol, January 2023 (epub ahead of print)
Differential inhibition of T cell receptor and STAT5 signalling pathways determine the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
Harrington P et al. Haematologica, January 2023
(epub ahead of print)
– open access publication
A systematic review on second treatment-free remission (TFR) attempt in chronic myeloid leukemia (CML): Can it be applied in clinical practice? - Review
Çiftçiler R et al. Clin Lymphoma Myeloma Leuk (epub ahead of print)
  Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring
Bataller A et al. Leuk Lymphoma, January 2023 (epub ahead of print)
  Is it time to reconsider molecular response milestones in CML?
Walia A and Prasad V. Am J Hematol, January 2023 (epub ahead of print)

Photo Ehab Atallah 2

Professor of Medicine
Associate Cancer Service Line Director

Division of Hematology & Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin (USA)


Ehab Atallah is a Professor of Medicine at the Medical College of Wisconsin Division of Hematology and Oncology, specialising in leukemia, myelodysplastic syndromes, myeloproliferative neoplasms and other bone marrow failure disorders in Froedtert Hospital in Milwaukee (USA).

He graduated from Cairo University School of Medicine and completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he also served as Chief Fellow. Following this, he completed a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas.

Dr Atallah’s current research interests are treatment of patients with CML, AML, CLL, ALL, myeloproliferative neoplasms and myelodysplastic syndromes. He is also the administrative director of the H Jean Khoury Cure CML Consortium (HJKC3). The HJKC3 is a collaborative effort of physicians and researchers at 21 academic medical centers committed to CML research and improving patient care and quality of life.

Clinical Publications Scientific Publications
December 2022
Project Confirm: Accelerated drug approvals for chronic myeloid leukemia
Sweet KL et al. Clin Cancer Res, December 2022
(epub ahead of print)
 
Management of TKI-resistant chronic phase CML - Review
Hughes TP and Shanmunagathan N. Hematology Am Soc Hematol Educ Program,
December 2022 
Genetic landscape of chronic myeloid leukemia - Review
Ochi Y. Int J Hematol, December 2022
(epub ahead of print)
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic-phase: the ASC4FIRST phase III trial
Cortes JE et al. Future Oncol, December 2022
(epub ahead of print)
- open access publication 
Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
Bütow M et al. Haematologica, December 2022
(epub ahead of print)
– open access publication
Treatment of CML in pregnancy
Robertson HF and Apperley JF. Hematology Am Soc Hematol Educ Program, December 2022 
Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
Karg E et al. Front Oncol, December 2022
– open access publication
Measurable residual disease in leukemia - Review
Branford S and Apperley JF. Haematologica, December 2022
open access publication 
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism
Gonzalez MA et al. Clin Transl Med, December 2022
– open access publication
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM1 trial
Dulucq S et al. Haematologica, December 2022
– open access publication
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
Tarantini F et al. Hematology, December 2022
Chronic myeloid leukemia: the cutting-edge evidence and things we should know
Iriyama N et al. Int J Hematol, December 2022
(epub ahead of print)
Wee 1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-yH2AX-MDC1
Zeng F et al. Cell Commun Signal, December 2022
– open access publication
De novo lymphoid blast phase chronic myeloid leukemia: report and contemporary discussion
Hameed M et al. Hematology, December 2022
– open access publication 
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicated chronic myeloid leukemia cells
Dudka W et al. BMC Cancer, December 2022
– open access publication
Current management of chronic myeloid leukemia myeloid blast crisis - Review
Yohanan B and George B. Clin Med Insights Oncol, December 2022 (epub ahead of print) 
Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells
Zhang J et al. Hematology, December 2022
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia - Review
Ahmed K et al. Front Med (Lausanne), December 2022
– open access publication 
Aberrant DNA methylation status and mRNA expression level of SMG1 gene in chronic myeloid leukemia: A case-control study
Hojjatipour T et al. Cell J, December 2022
A review of the therapeutic role of the new third-generation TKI Olverembatinib in chronic myeloid leukemia - Review
Qian H et al. Front Oncol, December 2022
- open access publication
Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients
Zhang Y et al. Hematology, December 2022
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
Ono T et al. Int J Hematol, December 2022
– open access publication 
FUBP3 regulates chronic myeloid leukemia progression through PRC2 complex regulated PAK1-ERK signalling
Sharma M et al. J Cell Mol Med, December 2022
(epub ahead of print)
– open access publication
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Ureshino H et al. Hematology, December 2022
– open access publication
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor
Liu H et al. Eur J Med Chem, December 2022
Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C and Kröger N. Hematology Am Soc Hematol Edu Program, December 2022
miR-495-3p sensitizes BCR-ABL1 expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance1 gene in T315I mutated cells
Rittavee Y et al. Exp Hematol, December 2022
(epub ahead of print)
 

Dvl proteins regulate SMAD1, AHR, mTOR, BRD7 protein expression while differentially regulating canonical and non-canonical Wnt signaling pathways in CML cell lines
Caliskan C et al. Gene, December 2022 (epub ahead of print)

November 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Flynn KE et al. Haematologica, November 2022
– open access publication
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
Parry N et al. Cell Death Discov, November 2022
– open access publication 
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands
Ector GICG et al. Leuk Lymphoma, November 2022 (epub ahead of print)
Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid leukemia
Ma J et al. Int J Mol Sci, November 2022
– open access publication 
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Jabbour E et al. Am J Hematol, November 2022
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
Knight A et al. Cancer Immunol Immunother, November 2022 (epub ahead of print) – open access publication 
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotonib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis - Review
Li S et al. Front Cardiovas Med, November 2022
- open access publication
Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia
Ma D et al. Oncogene, November 2022
(epub ahead of print)
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with chronic myeloid leukemia
Ono T et al. Cancer Sci, November 2022 (epub ahead of print) – open access publication
Low c-Kit expression identifies primitive therapy-resistant CML stem cells
Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication
Olverembatinib in chronic myeloid leukemia
Öziskender R et al. Drugs Today (Barc), November 2022
Hematopoietic and chronic myeloid leukemia stem cells:
Multi-stability versus lineage restriction - Review
Brown G. Int J Mol Sci, November 2022
– open access publication
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation
Xu Z et al. Leuk Lymphoma, November 2022
SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia
Wu DL eta l. Eur J Med Res, November 2022
– open access publication
Extramedullary T-lymphoblastic blast crisis in chronic myeloid leukemia:
A very rare case associated with comutation of ABL1 T315I and H396R
Zhang Y et al. Int J Lab Hematol, November 2022 (epub ahead of print)
Reciprocal interactions among CobII1, PACSIN2, and SH3BP1 regulate drug resistance in CML
Park K et al. Cancer Med, November 2022
– open access publication
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast crisis and was successfully treated with asciminib
Tomassetti S et al. Clin Case Rep, November 2022
– open access publication

Low c-Kit expression identifies primitive therapy-resistant CML stem cells
Shah M et al. JCI Insight, November 2022
(epub ahead of print)
– open access publication

 
October 2022
Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party in the EBMT
Chalandon Y et al. Am J Hematol, Oct 2022
(epub ahead of print) – open access publication
Secondary fusion proteins as a mechanism of BCR::ABL1 kinase independent resistance in chronic myeloid leukemia
Barnes EJ et al. Br J Haematol, Oct 2022
(epub ahead of print)
Dasatinib plus Peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukemia: Results of a multicenter phase 2 study (DASA-Peg IFN Study)
Roy L et al. Br J Haematol, Oct 2022
(epub ahead of print)
Prognostic impact of ASXL1 mutations in chronic phase CML
Bidikian A et al. Blood Cancer J, Oct 2022
– open access publication
B-lymphoid blast phase chronic myeloid leukemia: Current Therapeutics
Yohannan B and George B. Int J Mol Sci, Oct 2022 – open access publication
Non-coding RNAs are implicit in chronic myeloid leukemia therapy-resistance - Review
Rudich A et al. Int J Mol Sci, Oct 2022
– open access publication
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Hochmann MJ et al. Int J Hematol, Oct 2022
(epub ahead of print
ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescene by regulating SIRT1/p53/p21 pathway
Liu W et al. Sci Rep, Oct 2022
– open access publication 
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency
Hochmann MJ et al. Int J Hematol, Oct 2022
(epub ahead of print)
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
Su YL et al. Cancer Sci, Oct 2022
– open access publication 
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia - Review
Senapati J et al. Leukemia, Oct 2022
(epub ahead of print)
IRF4 Gene expression on the trail of molecular response: looking at chronic myeloid leukemia from another perspective
Tarantini F et al. Acta Haematol, Oct 2022
(epub ahead of print
Real-world therapeutic response and tyrosine kinase discontinuation in chronic-phase chronic myeloid leukemia: data from the French Observatory
Saugues S et al. Ann Hematol, Oct 2022
Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling
Yiu X et al. Cell Death Dis, Oct 2022
– open access publication
Bosutinib-induced late-onset severe liver injury preceded by eopsinophilia
Watanabe N et al. Ann Hematol, Oct 2022
 
BCR::ABL1 levels at first month after tyrosine kinase inhibitor discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC”
Di Giusto S et al. Cancer Med, Oct 2022
(epub ahead of print) – open access publication
 
Volumetric dried blood micro-sampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia
Krützmann ME et a. J Pharm Biomed Anal, Oct 2022 (epub ahead of print)
Co-existence of chronic lymphocytic leukemia and chronic myeloid leukemia and underlying pathogenetic mechanisms
Badal S et al. Eur J Haematol, Oct 2022 (epub ahead of print)
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care
Assanto GM et al. Expert Rev Hematol, Oct 2022 (epub ahead of print)
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells
Vinothkumar K et al. Int J Hematol, Oct 2022
(epub ahead of print)
CML resistant to 2nd generation TKI’s: Mechanisms, next steps, and new directions
Scalzulli E et al. Curr Hematol Malig Rep, October 2022 (epub ahead of print)
Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways
Janowski M et al. Onco Targets Ther, Oct 2022 – open access publication
 

Association between germline single-nucleotide variants in ADME genes and major molecular response to imatinib in CML patients
Estrada N et al. J Clin Med, Oct 2022

September 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
Schönfeld L et al. Leukemia, September 2022
– open access publication 
IFN- α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
Huuhtanen J et al. J Clin Invest, September 2022
– open access publication 
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour E and Kantarjian H. Am J Hematol,
September 2022
Targeting the PTP1B-BCR-ABL1 interaction for the degradation of T315I mutant BCR-ABL1 in chronic myeloid leukemia
Elgehama A et al. Cancer Sci, September 2022
(epub ahead of print) – open access publication 
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era
Vaughn JL et al. Bone Marrow Transplant, September 2022 (epub ahead of print)
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia
Soverini S et al. Leukemia, September 2022 
Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population
Kockerols CCB et al. Haematologica, September 2022 (epub ahead of print) – open access publication
Ex vivo expansion of phenotypic and transcriptome CML stem cells
Patel SB et al. Exp Hematol, September 2022
(epub ahead of print) – open access publication 
Deep molecular response in patients with chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TMT614 combined with a tyrosine kinase inhibitor
Takahashi N et al. Cancer Med, September 2022
(epub ahead of print) – open access publication
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance
Bührer ED et al. Leukemia, September 2022 (epub ahead of print) – open access publication 
Management of chronic myeloid leukemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicine Agency (AIFA)
Breccia M et al. Br J Haematol, September 2022
– open access publication
circCRKL, a circ RNA-derived from CRKL, regulates BCR-ABL via sponging miR-877-p5 to promote chronic myeloid leukemia cell proliferation
Wang J et al. J Transl Med, September 2022
– open access publication 
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities – Review
Narli Özdemir Z et al. Int J Hematol, September 2022 (epub ahead of print)
KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukemia though activating Wnt/ß-catenin pathway
Huang Y et al. Clin Exp Pharmacol Physiol, September 2022
(epub ahead of print)
open access publication
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia – Review
Umezawa Y and Sasaki K. Int J Hematol, September 2022 (epub ahead of print)
 
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitors?
Canon A et al. Leuk Lymphoma, September 2022
(epub ahead of print)
 
Asciminib vs bosutinib in CML patients pretreated with ≥ 2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL Study
Yuda J et al. Cancer Med, September 2022
(epub ahead of print) – open access publication
 
A unique three-way variant Philadelphia chromosome t(6;9;22) (p21.3;q34;q11.2) in a newly diagnosed patient with chronic myeloid leukemia responded to Flumatinib
Chen L et al. Onco Targets Ther, September 2022
– open access publication
 
August 2022
Defining higher-risk chronic myeloid leukemia: risk scores, genomic landscape, and prognostication – Review
Shahrin NH et al. Curr Hematol Malig Rep, August 2022 (epub ahead of print) - open access publication
Reengineering ponatinib to minimize cardiovascular toxicity
Hnatiuk AP et al. Cancer Res, August 2022 
Onset of blast crisis in chronic myeloid leukemia in treatment-free remission
Dulucq S et al. Haematologica, August 2022
(epub ahead of print) – open access publication
Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in TKI-resistant CML cells
Kaehler M et al. Oncol Rep, August 2022
– open access publication 
Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia
Johnson-Ansah H et al. Pharmaceutics, August 2022 – open access publication
Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-alderosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia
Tsuda M et al. Int J Hematol, August 2022
(epub ahead of print) 
Asciminib as a third line option in chronic myeloid leukemia - Review
Laganà A et al. Int J Hematol, August 2022
(epub ahead of print)
Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors
Hong Y et al. Int Immunopharmacol, August 2022 
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
Kockerols CCB et al. Haematologica, August 2022 – open access publication
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR:ABL1-independent resistance to tyrosine kinase inhibitors
Mancini M et al. Front Oncol, August 2022
– open access publication
Caution in using second generation tyrosine kinase inhibitor, especially for first-line therapy of chronic myeloid leukemia
Gambarcorti-Passerini C et al. Am J Hematol, August 2022 – open access publication
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Yen R et al. Leukemia, August 2022 (epub ahead of print
Real-life analysis and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Luna A et al. Ann Hematol, August 2022
(epub ahead of print) – open access publication
The mRNA expression of PTEN, LEF1, JAK3, LC3, and p62/SQSTM1 genes in patients with chronic myeloid leukemia
Lak ER et a. Cardiovas Hematol Agents Med Chem, August 2022 
Olverembatinib (HQP135I), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated CML: results of an open-label, multicenter phase 1/2 trial
Jiang Q et al. J Haematol Oncol, August 2022
– open access publication
Activin A downregulates the CD69-MT2A axis via p38 MAPK to induce erythroid differentiation that sensitized BCR-ABL-positive cells to imatinib
Chen CW et al. Exp Cell Res, August 2022
TKI dosing for chronic phase CML: the case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)
Tefferi A et al. Am J Hematol, August 2022
(epub ahead of print)
 
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Yen R et al. Leukemia, August 2022
(epub ahead of print)
 
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Hehlmann R et al. Leukemia, August 2022
(epub ahead of print) – open access publication 

July 2022
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors
Aslan NA et al. J Oncol Pharma Pract, July 2022
– open access publication
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Sánchez R et al. Sci Rep, July 2022
– open access publication
Mechanisms of resistance and implications for treatment strategies in CML - Review
Poudel C et al. Cancers(Basel), July 2022
– open access publication
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
Su YJ et al. Cancer Sci, July 2022 (epub ahead of print)
– open access publication 
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase - Review
García-Gutiérrez V et al. J Hematol Oncol, July 2022 – open access publication
RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
Zhang H et al. Haematologica, July 2022
(epub ahead of print) – open access publication
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Haddad FG et al. Am J Hematol, July 2022
Vandetanib drives growth arrest and promotes sensitivity to Imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4
Ma W et al. Mol Oncol, July 2022
– open access publication
Exposure-efficacy analysis of Asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase
Combes FP et al. Clin Pharmacol Ther, July 2022
(epub ahead of print)
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
Peter B et al. Am J Hematol, July 2022
(epub ahead of print)-  open access publication
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor chronic myeloid leukemia patients
Lipton NJ and Lipton JH. Leuk Lymphoma, July 2022
Chronic myeloid leukemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype
Harrington P et al. Br J Haematol, July 2022
(epub ahead of print) – open access publication
Induction-maintenance for the chronic-phase of chronic myeloid leukemia (IMPACT-I): a prospective, single-arm, phase 2 study
Cheung YM et al. Lancet Oncol, July 2022
Allosteric enhancement of the BCR-ABL1 kinase inhibition activity of Nilotinib by co-binding of Asciminib
Oruganti B et al. J Biol Chem, July 2022
(epub ahead of print) – open access publication
Co-variates associated with outcomes of tyrosine kinase inhibitor therapy in persons with chronic myeloid leukemia initially presenting in accelerated phase
Yang S et al. Leukemia, July 2022
Complex karyotype with double Philadelphia chromosome and T315l mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient
Davulcu EA et al. Cancer Genet, July 2022
(epub ahead of print
Migrating to long-read sequencing for clinical routine BCR-ABL1 TKI resistance mutation screening
Schaal W et al. Cancer Inform, July 2022
– open access publication
Simultaneous quantification of Dasatinib, Nilotinib, Bosutinib, and Ponatinib using high-performance liquid chromatography-Photodiode array detection
Yokoyama Y et al. J Clin Lab Anal, July 2022
(epub ahead of print) – open access publication 
Treatment of blast phase chronic myeloid leukemia: A rare and challenging entity – Review
Copland M. Br J Haematol, July 2022
(epub ahead of print) – open access publication
 Inability to phosphorylate Y88 of P27Kip1 enforces reduced P27 protein levels and accelerated leukemia progression
Jäkel H et al. Leukemia, July 2022
– open access publication
Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases
Abdelmagid MG et al. Blood Cancer J
– open access publication
 
June 2022
Asciminib for chronic myeloid leukemia: Next questions - Review
Shanmuganathan N and Hughes TP. Br J Haematol, June 2022 (epub ahead of print)
CRISPR/Cas9-directied gene trap constitutes a selection system for corrected BCR/ABL leukemic cells in CML
Vuelta E et al. Int J Mol Sci, June 2022
– open access publication
Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia
Branford S. Turk J Haematol, June 2022
(epub ahead of print) – open access publication
Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
Liu C et al. Cell Metabol, June 2022 
French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia (In French)
Réa D et al. Bull Cancer, June 2022 (epub ahead of print)
The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug
Teng M et al. J Med Chem, June 2022
(epub ahead of print) 
Chronic myeloid leukemia: 2022 update on diagnosis, therapy and monitoring
Jabbour E and Kantarjian H. Am J Hematol, June 2022 (epub ahead of print)
BCR-ABL1∆E7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Tan Y et al. Hematol Oncol, June 2022
(epub ahead of print
Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy
Zhang XS et al. Leukemia, June 2022
(epub ahead of print)
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
Salmon M et al. Leukemia, June 2022
(epub ahead of print) – open access publication
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukemia at high risk of cardio toxicity
Di Lisi D et al. ESC Heart Fail, June 2022
open access publication
Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission
Yu G et a. Leuk Lymphoma, June 2022
(epub ahead of print)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dentritic Neoplasms - Review
Khoury JD et al. Leukemia, June 2022
(epub ahead of print) – open access publication
Successful preservation of native BCR::ABL1 in chronic myeloid leukemia primary leukocytes reveals a reduced kinase activity
Boni C et al. Front Oncol, June 2022
– open access publication
Future management of chronic myeloid leukemia: From dose optimization to new agents
Breccia M et al. Curr Cancer Drug Targets
(epub ahead of print)
Modified dentritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
Du Z et al. Exp Hematol Oncol, June 2022
open access publication
The outcomes of ponatinib therapy in patients with CML resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the Donation Program
Sacha T et al. Clin Lymphoma Myeloma, June 2022
– open access publication
Atypical activation of signaling downstream of inactivated BCR-ABL mediates chemoresistance in chronic myeloid leukemia
Narasimhan M et al. J Cell Commun Signal, June 2022 (epub ahead of print) – open access publication
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia:
a post-marketing surveillance study in Korea
Ahn SY et al. Blood Res, June 2022
(epub ahead of print)
– open access publication
Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia
Ozel B et al. Med Oncol, June 2022
Out comes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
Sanz A et al. Blood Cancer J, June 2022
– open access publication
 
Bosutinib-induced lung injury: a report of two cases and literature review
Watanabe N et al. Int J Hematol, June 2022
– open access publication
 
May 2022
How I treat chronic-phase chronic myelogenous leukemia
Berman E. Blood, May 2022
Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors
de Almeida FC et al. Front Immunol, April 2022
– open access publication
Asciminib: new therapeutic option in chronic-phase CML with treatment-failure
Yeung DT et al. Blood, April 2022 (epub ahead of print)
RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia
Shanmunagathan N et al. J Mol Diagn, May 2022
(epub ahead of print)
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
Lu L et al. Br J Haematol, May 2022
(epub ahead of print) – open access publication
Novel tyrosine kinase inhibitors to target chronic myeloid leukemia
Ciaffaglione V et al. Molecules, May 2022
– open access publication
Chronic myeloid leukemia: a type of MPN
Samad MA et al. Blood Res, May 2022
(epub ahead of print)
– open access publication
Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects
Senapati J and Sasaki K. Cancers(Basel), May 2022
– open access publication
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia – What to look for when treatment-free remission is not an option
Lipton JH et al. Blood Rev, May 2022
(epub ahead of print) – open access publication 
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients
Shehata AMF et al. Leuk Res, May 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
Brümmendorf TH et al. Leukemia, May 2022
(epub ahead of print) – open access publication

Peripheral blood CD26 positive leukemia stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia
Ebjan HF et al. Leuk Res Rep, May 2022
– open access publication

 
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
Flynn KE et al. Haematologica, May 2022
(epub ahead of print) – open access publication
 
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
White HE et al. Leukemia, May 2022
(epub ahead of print) – open access publication
 
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
Yang J et al. Expert Rev Hematol, May 2022
(epub ahead of print)
 
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM-2 trial
Dulucq S et al. Haematologica, May 2022
(epub ahead of print) – open access publication
 
Lower tumour burden is associated with better cognitive function in patients with chronic-phase chronic myeloid leukemia
Li Z et al. Leuk Lymphoma, May 2022
(epub ahead of print)
 
Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience
Szczepanek E et al. Leuk Lymphoma, May 2022
(epub ahead of print)
 
April 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
Gugliotta G et al. Haematologica, April 2022
(epub ahead of print) – open access publication
Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide
Zheng X et al. Oncol Lett, April 2022
– open access publication 
 
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success
Inzol E et al. Am J Hematol, April 2022
(epub ahead of print) – open access publication
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Adnan Awad S et al. Blood Cancer J, April 2022
– open access publication 
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
Haddad F et al. Leuk Lymphoma, April 2022
(epub ahead of print)
Aberrant hyrdroxymethylation in promoter CpG regions of genes related to the cell cycle apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival
Guru SA et al. BMC Cancer, April 2022
open access publication
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation
Shimazu Y et al. Hematol Oncol, April 2022
(epub ahead of print)
Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy
Li Y et al. Cell Death Discov, April 2022
– open access publication 
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukemia
Shivarov V and Grigorova D. Br J Haematol, April 2022 (epub ahead of print) – open access publication
 
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic leukemia in the United Kingdom and The Netherlands
Claudiani S et al. Eur J Haematol, April 2022
(epub ahead of print)
 
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization?
Bhreathnach Ú and Langabeer SE. Int J Lab, April 2022 (epub ahead of print) – open access publication
 
Aleukemic extramedullary blast crisis as an initial presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion transcript
Miyashita N et al. Int Med, April 2022 (epub ahead of print)
– open access publication
 
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
García-Gutiérrez V and Hernandez-Boluda JC. Expert Rev Hematol, May 2022 (epub ahead of print)
 
March 2022
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
Takahashi N et al. Int J Hematol, March 2022
(epub ahead of print) – open access publication
Another Philadelphia story
Radich J. Haematologica, March 2022
– open access publication
Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in hematology
Saglio G et al. Bone Marrow Transplant, March 2022 (epub ahead of print) – open access publication
The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients
Park H et al. Leuk Res, March 2022
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in real-life: A Campus CML study
Iurlo A et al. Front Oncol, March 2022
– open access publication
The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
Kumar R et al. Blood Adv, March 2022
(epub ahead of print) – open access publication
Prevalence of anemia among chronic myeloid leukemia patients treated with imatinib: A evidence based meta-analysis
Singh AK et al. Curr Rev Clin Exp Pharmacol, March 2022 (epub ahead of print)
Targeting BCR-ABL in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Roskoski R. Pharmacol Res, March 2022
(epub ahead of print)
Molecular monitoring of BCR-ABL fusion transcripts in patients with chronic myeloid leukemia during treatment using the endpoint fluorescence method
Amin H and Ahmed S. Lab Med, March 2022
A kinase inhibitor which specifically targets the ABL myristate pocket (STAM), but unlike asciminib crosses the blood-brain barrier
Manley PW et al. Bioorg Med Chem Lett, March 2022
The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation
Tachibana T et al. Transplant Cell Ther, March 2022 (epub ahead of print)
FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via non-canonical κB-kappa B signaling activation
Yang T et al. J Exp Clin Cancer Res, March 2022
– open access publication
Outcomes of pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review
Castillo DL et al. Hematol Rep, March 2022
– open access publication
Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapyExpression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapy
Toloza MJ et al. Gene, March 2022
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentrations in patients with chronic myeloid leukemia receiving first-line nilotinib therapy
Fukuda N et al. Cancer Chemother and Pharmacol, March 2022 (epub ahead of print)
– open access publication
MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukemia cells to imatinib by inhibiting mTor signalling
Liu X et al. Acta Hematol, March 2022
(epub ahead of print)
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukemia
Baccarani M et al. Leukemia, March 2022
(epub ahead of print) – open access publication
 
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukemia model
Lindström HJG and Friedmann R. Sci Rep,
March 2022 – open access publication
 
February 2022
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation
Shatty D et al. Asia Pac J Clin Oncol, February 2022
– open access publication 
TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells
Sun H et al. Int J Oncol, March 2022
(epub ahead of print)
– open access publication
Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A Pairwise and Bayesian Network Meta-Analysis
Chen K et al. Front Oncol, February 2022
– open access publication 
A systematic review of candidate miRNAs, its targeted genes and pathways in CML – An integrated bioinformatical analysis
Elias MH et al. Front Oncol, March 2022
– open access publication
Extramedullary early T-cell lymphoblastic crisis in a young pregnant chronic myeloid leukemia patient: Diagnosis with fine needle aspiration cytology and flow cytometry
Murugan R et al. Diagn Cytopathol, Feb 2022 (epub ahead of print
Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia cells
Ianniciello A and Helgasson GV. Autophagy, March 2022
(epub ahead of print)
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive phase in Taiwan
Hwang WL et al. Int J Hematol, February 2022 (epub ahead of print
Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, March 2022
– open access publication
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
Shelton DN et al. PLoS One, March 2022
– open access publication
Commentary on Dominy et al.: Assessment of qualitative PCR for BCR-ABL1 transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Branford S. Br J Haematol, February 2022
(epub ahead of print)
– open access publication
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Robin JB et al. Ann Hematol, March 2022
(epub ahead of print)
Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print)
Management of chronic myeloid leukemia and pregnancy:
A Bibliometric Analysis (2000-2020)
Wang Y et al. Front Oncol, March 2022
– open access publication
Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication
Transcript and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Kumar V et al. Mol Cell Biochem, February 2022 (epub ahead of print
Genomic mechanisms influencing outcome in chronic myeloid leukemia
Fernandes A et al. Cancers(Basel), January 2022 – open access publication
Olverembatinib: First Approval
Dhillon S et al. Drugs, February 2022
(epub ahead of print)
Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission
Stuckey R et al. Curr Oncol Rep, February 2022
(epub ahead of print)
A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy
Zhang XS et al. Leukemia, February 2022
(epub ahead of print)
Validation and refinement of RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia
Lee KL et al. Leukemia, February 2022
(epub ahead of print)
– open access publication
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
Pokorny R et al. J Oncol Pharm Pract, February 2022
(epub ahead of print)
– open access publication 
Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia
Kamachi K et al. Cancer Lett, February 2022 – open access publication 
  Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022
  Waking up CML leukemia stem cells for the kill
Lv K and Tong W. Blood, February 2022
– open access publication 
  Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia
Sharma P et al. Int J lab Hematol, February 2022
(epub ahead of print
  Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study)
Sicuranza A et al. Front Oncol, February 2022 – open access publication 

 

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Closa L et al. HLA, February 2022 
January 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukemia
Gallipoli P et al. Br J Haematol, January 2022
(epub ahead of print)
– open access publication
The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemia cell differentiation
Shahzad Ali M et al. J Clin Med, January 2022
– open access publication
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
Januzzi JL et al. J Hematol Oncol, January 2022
– open access publication
BCR-ABL1 tyrosine kinase complex signalling transduction:
challenges to overcome resistance in chronic myeloid leukemia

Amarante-Mendes GP et al. Pharmaceutics, January 2022
– open access publication
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors:
Follow-up of patients diagnosed 2002 – 2017 in a complete coverage and nationwide agnostic register study
Dahlén T et al. Am J Hematol, January 2022
(epub ahead of print)
– open access publication
Imatinib can act as an allosteric activator of ABL kinase
Xie T et al. J Mol Biol, January 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
Réa D and Hughes TP. Crit Rev Oncol Hematol,
January 2022
(epub ahead of print)
– open access publication
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
Tanaka Y et al. Nat Commun, January 2022
– open access publication
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM et al. Br J Haematol, January 2022
(epub ahead of print)
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis
Louati N et al. J Oncol Pharma Pract, January 2022
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: Who can benefit the most?
Efficace F and Baccarani M. J Natl. Cancer Inst,
January 2022
– open access publication
Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases
Schwarz A et al. Cancers(Basel), January 2022
– open access publication
The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review
Arzoun H et al. Cureus, January 2022
– open access publication
P-Loop mutations-negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients
Kaleem B et al. Int J Lab Hematol, January 2022
(epub ahead of print)
Asciminib: First Approval
Deeks ED et al. Drugs, January 2022
(epub ahead of print)
The prognosis biomarkers based on m6A-related IncRNAs for myeloid leukemia patients
Yang LR et al. Cancer Cell Int, January 2022
– open access publication
Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors
Shaya J et al. Clin Lymphoma Myeloma Leuk, January 2022
– open access publication
Pterostilbene downregulated BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
Kawakami S et al. Sci Rep, January 2022
– open access publication

Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Kee KM et al. Leuk Res, January 2022

Novel mechanism by a Bis-Pyridinium fullerene derivate to induce apoptosis by enhancing the MEK-ERK pathway in a reactive oxygen species-independent manner in BCR-ABL-positive chronic myeloid leukemia-derived K562 cells
Sumi K et al. Int J Mol, January 2022
– open access publication